Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma

Full text
Author(s):
de Souza, Mariana Barbosa [1] ; Curioni, Otavio Alberto [2] ; Kanda, Jossi Ledo [3] ; De Carvalho, Marcos Brasilino [4]
Total Authors: 4
Affiliation:
[1] Univ Sao Paulo. Sch Med
[2] Heliopolis Hosp. Mol Biol Lab
[3] Padre Anchieta Teaching Hosp. ABC Med Sch
[4] Heliopolis Hosp. Mol Biol Lab
Total Affiliations: 4
Document type: Journal article
Source: Oncology Letters; v. 8, n. 5, p. 2267-2275, NOV 2014.
Web of Science Citations: 10
Abstract

The overexpression of macrophage migration inhibitory factor (MIF) has been identified in a variety of tumors and the investigation of its molecular mechanisms in tumor progression is a key topic of research. The present study aimed to investigate MIF as a potential marker for disease control or recurrence, and to assess the association between serum and salivary MIF and the clinicopathological characteristics of patients with oral squamous Cell carcinoma (OSCC). Serum and salivary samples were collected prior to and following the surgical treatment of 50 patients with OSCC. MIF concentrations were assessed by enzyme-linked immunosorbent assay and the adopted level of statistical significance was P<0.05. The results revealed that serum MIF concentrations were significantly reduced following tumor resection in OSCC patients. Furthermore, higher preoperative salivary MIF concentrations were observed in patients with larger tumors and in those who succumbed to the disease. In conclusion, high salivary and serological MIF concentrations were identified in patients with OSCC. Nevertheless, only serological MIF concentrations may be considered as a potential marker for the early detection of OSCC recurrence once the salivary levels, prior and following treatment, do not show any significant differences. (AU)

FAPESP's process: 11/03281-5 - Evaluation of expression of macrophage migration inhibitory factor (MIF) as prognostic marker in patients with oral squamous cell carcinoma
Grantee:Mariana Barbosa de Souza Rizzo
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 10/20765-3 - Evaluation of expression of macrophage migration inhibitory factor (MIF) as prognostic marker in patients with squamous cell carcinoma of the oral cavity
Grantee:Marcos Brasilino de Carvalho
Support Opportunities: Regular Research Grants